Held May 13-16.

Argos Therapeutics presents AGS-004 autologous dendritic cell therapy Stage 2a trial data in 19th CAHR Today announced the display of data from the Phase 2a trial of AGS-004 Argos Therapeutics, demonstrating that the personalized immunotherapy includes a positive effect on the genetic diversity of residual HIV virus, and also outcomes in substantially increased period to viral rebound in HIV sufferers treated with AGS-004 following antiretroviral therapy interruption. The info were discussed within an oral display at the 19th Annual Canadian Conference on HIV/AIDS Analysis , held May 13-16, 2010 in Saskatoon, Saskatchewan.Professor Malcolm Dunlop, of the Medical Analysis Council Human Genetics Device at the University of Edinburgh, said: ‘Our results are promising nonetheless it is essential to note that that is an observational research. We need carefully designed randomised medical trials before we are able to confirm whether taking supplement D supplements presents any survival advantage for bowel cancer sufferers.’.

Catalyst Pharmaceutical Partners announces top-line results of CPP-109 phase II trial for cocaine addiction Catalyst Pharmaceutical Companions, Inc.